Trial Shows Promise in Reducing Side Effects of Blood Thinners for Some Stroke Patients

Thank you. Listen to this article using the player above. ✖

The results of a clinical trial have shown that a drug commonly used for patients with bleeding disorders has the potential to be used to lessen the side effects of blood-thinning drugs for patients who have experienced a stroke.

Researchers from the University of Nottingham and Oxford University Hospitals NHS Foundation Trust assessed the suitability of Desmopressin to be used in larger trials to help reduce the number of people who die or are disabled after intracerebral haemorrhage. The results from the DASH trial, which was funded by the National Institute for Health and Care Research (NIHR), have been published in The Lancet Neurology.

Approximately 3 million deaths each year are due to spontaneous intracerebral haemorrhage worldwide and there is currently no proven effective drug treatment. Researchers estimate that two-thirds of survivors are left dependent on others and a quarter of patients were taking antiplatelet drugs at the time of incident.

Patients from 10 hospitals across the UK, who had suffered an intracerebral haemorrhage while taking antiplatelet drugs, took part in the clinical trial. One group were given Desmopressin whilst a second group was given a ‘dummy drug’.

Dr Michael Desborough, Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, said: “Intracerebral haemorrhage for people taking antiplatelet drugs leads to thousands of deaths every year. Unfortunately, at present there are no treatments available. The results of the DASH trial are an important step towards assessing whether desmopressin might reduce the high risk of death or disability from intracerebral haemorrhage worldwide.”

Professor Nikola Sprigg, Stroke Trials Unit, University of Nottingham, added: “Whether Desmopressin reduces the number of people who die or are disabled after intracerebral haemorrhage is an important question to answer. These findings support the need for a definitive, large-scale trial to determine if desmopressin improves outcomes in patients with intracerebral haemorrhage on antiplatelet drug therapy.”

Reference: Desborough MJR, Salman RAS, Stanworth SJ, et al. Desmopressin for patients with spontaneous intracerebral hemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomized, placebo-controlled, multicentre feasibility trial. Lancet Neurol. 2023;22(7):557-567. doi: 10.1016/S1474-4422(23)00157-6

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.